USPTO grants patent titled 'method of therapeutic administration of DHE' to MAP Pharma

The United States Patent and Trademark Office (USPTO) issued to the MAP Pharmaceuticals' US Patent No. 8,119,639, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile."  

The patent, which expires in 2028, results from the company's discovery that dihydroergotamine (DHE) can be administered to achieve pharmacokinetic profiles that result in rapid efficacy while minimizing side effects that are typically seen with other migraine drugs.  The patent claims relate to pulmonary administration of DHE to achieve certain pharmacokinetic profiles. Levadex, which contains the company's proprietary formulation of DHE, is an orally inhaled investigational drug administered using the company's proprietary Tempo inhaler for the potential acute treatment of migraine in adults and targets the pharmacokinetic profiles described in this patent.